Product Code: RP-ID-10008242 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10008242
Market Overview:
Global Cancer Biomarkers Market Size, Growth, Opportunity and Forecast 2022-2030
" The global cancer biomarkers market is estimated to be ~USD 18 billion by the end of 2021 and is expected to expand at a CAGR of ~12% over the period 2022-2030. Cancer is the second leading cause of death in the United States after heart disease due to positive growth in this market. In the United States, the prevalence of breast, prostate, and lung malignancies is increasing rapidly, with approximately 1,600 cases per year. In 2017, there were approximately 200,000 cases of breast cancer in the United States.
Patients and healthcare professionals are increasingly aware of the importance of early diagnosis of malignant tumors, and the growing demand for personalized medicine is expected to provide huge growth opportunities for this cancer biomarker market in the next decade.
Diagnostic biomarkers used for early diagnosis enable doctors to decide on better treatment alternatives and thus a successful recovery in a shorter time. In addition, it is estimated that increased regulatory approvals for new drugs and diagnostic methods related to cancer biomarkers will increase the adoption rate.
For example, in 2016, Epigenomics AG, a company involved in the development of new epigenetic biomarker tests, announced that the Chinese government would use its Epi proColon to detect colorectal cancer (CRC).
TYPE INSIGHTS:
According to type, the market is divided into breast, prostate, colorectal, cervix, liver and lung. Breast cancer is the biggest part of 2020. Breast cancer, lung cancer and prostate cancer accounted for more than 38% of revenue in 2016. Increasing awareness of early detection and growing population base targets are key factors contributing to dominance.
Lung cancer is expected to grow the fastest in the prognosis period. More and more diagnostic tests for EGFR and BRAF mutations are used as important biomarkers for the diagnosis of non-small cell lung cancer, which are expected to promote the growth of the market segment.
BIOMOLECULAR INFORMATION:
Based on biomolecules, the market is further subdivided into genetic, epigenetic, metabolic and proteomic biomarkers. Genetic biomarkers occupy a considerable market share due to their wide range of uses, high reliability, and easy analysis. According to reports, more than 85% of malignant tumors are detected with the help of genetic and proteomic biomarkers.
Epigenetics has been widely recognized in the field of cancer diagnosis. Many participants are conducting extensive research to analyze key epigenetic modifications related to cancer in order to further develop biomarkers for targeted drugs. Increased cooperation between pharmaceutical companies in the development of new drugs for epigenetic biomarkers is expected to drive growth in this area.
APPLICATION INFORMATION:
Cancer biomolecules have applications in various fields, including drug discovery and development, diagnosis and personalized medicine. Diagnosis is a major revenue-generating market application, related to factors such as the continuous development of biomarker-based cancer tests with high specificity and sensitivity.
Due to its growing demand and growing awareness among healthcare professionals, it is expected to witness a booming growth rate. In addition, the approval of more and more complementary diagnostic tests for cancer drugs is expected to affirm the market growth.
REGIONAL OUTLOOK:
North America dominates the regional market, followed by Europe. The high adoption of innovative technologies, the existence of key pharmaceutical companies, the established R&D infrastructure related to the development of new diagnostic products, and the growing demand for early and targeted diagnosis are the main factors in the above-mentioned areas.
An enabling environment for cancer screening, clinical trials, and increased government funding to support drug development programs are expected to achieve a lucrative compound annual growth rate during the forecast period. In addition, the growing attention of pharmaceutical companies in the region, coupled with increasing awareness of biomarker-based diagnostics, is one of the important drivers of growth.
CANCER BIOMARKER MARKET SHARE OUTLOOK:
Abbott Laboratories; F. Hoffmann-La Roche Ltd.; QIAGEN; Thermo Fisher Scientific; Affymetrix; Illumina, Inc.; Agilent Technologies; Merck; Hologic, Inc .;Huaxia Biological Co., Ltd.; Becton, Dickinson and Company are some of the major players in the market. The development of new products, cooperation with research institutions to develop new biomarkers, and mergers and acquisitions of small companies are key strategies for these companies to achieve stability and stability. market status.
SECTORS COVERED IN THIS REPORT:
This report forecasts global, regional and national sales growth and provides an analysis of industry trends in each sub-sector from 2022-2030. In this study, Kenneth Research presents Global Bio I looked into cancer, a marker market. and Molecular Viability, Types, Uses and Sectors: Forecast Type (Sales, $1 Billion, 2022-2030) Breast Cancer, Prostate Cancer, Major Colorectal Cancer, Uterine Cancer, Liver Cancer, Lung Cancer, etc. (Revenue, $1 Billion). 2022-2030) Research and development of other personalized medical diagnosis. "
1. Thermo Fisher Scientific
2. Bio-Rad Laboratories
3. Roche Diagnostics
4. Qiagen N.V.
5. Illumina
6. GE Healthcare
7. Agilent Technologies
8. Biomérieux SA
9. Merck & Co.
10. Abbott Laboratories
11. Becton, Dickinson and Company
12. Danaher Corporation
13. Myriad Genetics
14. Sysmex Corporation
15. Hologic
16. Quest Diagnostics
Related Reports
Proof of Quality & Reliability
